We know that docetaxel chemotherapy (chemo) extends life, but which men might hope to experience an increase in survival?
The Department of Urology, All India Institute of Medical Sciences, New Delhi, India performed a small study designed to evaluate the efficacy of docetaxel/prednisone and zoledronic acid in the treatment of men with hormone refractory prostate cancer (HRPC) as well as to analyze prognostic factors predicting overall survival.
This small study with Forty-four men with HRPC were given docetaxel (75 mg/m(2)), prednisone and zoledronic acid (4 mg) every three weeks. They then calculated the overall and progression-free survival curves. Using the log-rank test, variables predicting overall survival (age, Gleason score, baseline prostate-specific antigen